CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA

- Conference call to be hosted on Tuesday, December 11th at 9:00 a.m. Eastern time - - Encouraging clinical results presented at ASH from the ongoing Phase II trial in T-cell lymphomas - - Positive End-of-Phase II meeting held with the FDA for b...

CuraGen Corporation Regains NASDAQ Listing Compliance

...in late January, we have successfully advanced our lead clinical program CR011-vcMMAE into Phase II development, completed the sale of our interest in belinostat for approximately $38 million in cash thus far, removed $50.9 million in debt from our balance sheet, and announced a reduction in our burn rate guida...

CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

...of CuraGen Corporation. "We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future ne...raGen's potential economic benefits from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private...

CuraGen Reports Third Quarter 2007 Financial Results

...CR-NCI-EORTC International Conference. These results, along with additional belinostat data being reported in December at the 2007 ASH Annual Meeting, will allow ...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...

Belinostat in Medical Technology

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference

- Significant anti-tumor activity of combination IV belinostat in ovarian cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I - - Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical up...

CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, i...

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

- Enrollment completed in Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis - - Continued focus to define registrational path for belinostat in the treatment of cancer - - Conference call and webcast to be held ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of ...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

...0.67 per share, during the same period in 2007. Significant one time transactions during the second quarter of 2008 included the sale of the rights to belinostat to TopoTarget A/S for approximately $38 million in cash and the repurchase of $50.9 million of debt for $43.2 million in privately negotiated transact...

CuraGen Advances CR011-vcMMAE into Phase II

...rporation (Nasdaq: CRGN ) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising ...

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma

...he four posters discussing Phase I and Phase II clinical trial results with belinostat being presented at the AACR-NCI-EORTC International Conference. Conference...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen Announces Top-Line Phase II Results on Velafermin

...tics, October 22-26, 2007, in San Francisco, CA: belinostat Title: Phase II Multicenter Trial of belinostat (PXD101) in Combination with Carb...c Agents Title: A Phase I Study of Oral belinostat (PXD101) in Patients with Advance...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

...sentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clini...nd anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxe...mailto:info@curagen.com">info@curagen.com About belinostat ...

Belinostat in Biological News

Massey researchers induce cell death in leukemia

... bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporation and TopoTarget A/S), were examined in ...ly with both agents to induce cell death in human CLL cells. Romidepsin and belinostat are histone deacetylase (HDAC) inhibitors. "To the best of our knowle...

Belinostat in Biological Technology

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

Update on the Regulatory Strategy for Belinostat in PTCL COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (...

CuraGen Sells Ownership of Belinostat to TopoTarget A/S

- CuraGen to receive approximately $45 million in cash, stock and future milestone payments - - Provides updated financial guidance for 2008 - - Conference call to be hosted today at 9:00 a.m. EDT - BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- ...

CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma

BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center ...

TopoTarget Successfully Buys Back Full Control of Belinostat

Consolidates the Global Rights for the Product TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product TopoTarget Acquires US & RoW Rights From CuraGen Corporation COPENHAGEN, April 22 /PRNewswire/ -- -...

CuraGen Reports Third Quarter 2008 Financial Results

...50 per share, for the same period in 2007. Net income for the nine months ended September 30, 2008 and 2007 was primarily due to a gain of the sale of belinostat and a gain on the extinguishment of debt in the second quarter of 2008, and the sale of 454 Life Sciences Corporation in the second quarter of 2007. ...

CuraGen Reports Fourth Quarter and Year End 2007 Financial Results

...n excellent position to advance our core products, belinostat and CR011-vcMMAE, toward registrational developmen...d quarter of 2008; -- Updated Phase II results of belinostat in combination with carboplatin and paclitaxel...8; and -- Initiate Phase III trial of intravenous belinostat for the treatment of peripheral T-cell lymphom...

CuraGen Appoints Clinical Oncologist as VP of Medical Development

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...

CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer

...w on three oncology programs including velafermin, belinostat and CR011-vcMMAE. "Tim has done an outstanding jo... Phase II results from an ongoing trial evaluating belinostat in combination with carboplatin and paclitaxel... October from an ongoing trial evaluating oral belinostat for the treatment of advanced solid tumors at ...